Table 2.

Treatment-related outcomes of patients enrolled in RESPOND-2

Treatment Characteristics	PR48 (n=80)	BOC/RGT (n=162)	BOC/PR48 (n=161)
Experienced anemia – no. (%)	16 (20)*	70 (43)	75 (47)
Erythropoietin (EPO) use – no. (%)	17 (21)	66 (41)	74 (46)
Mean duration of anemia (days)	97.4	122.1	150.6
Mean duration of EPO use (days)	64.6	135.0	130.2
Discontinued before TW12 - n/m (%)	5/80 (6)	13/162 (8)	4/161 (2.5)
Discontinued due to treatment failure at TW12 - n/m (%)†	49/75 (65)	36/149 (24)	29/157 (18)
Discontinued after TW12 - n/m (%)†	3/26 (12)	7/113 (6)	23/128 (18)
Assigned 36 weeks therapy - n/m (%)†	NA	66/106 (62)	NA
Sustained virologic response (SVR) – no. (%)	17 (21)	95 (59)	107 (66)

^*All patients receiving EPO were assumed as anemic by the model. Since more patients received EPO than who experienced anemia in PR48, the number of patients who experienced anemia in PR48 were assumed to be 17 in the model.

^†Conditional on the proportion of subjects reaching this week in the trial (as needed by the model). The denominator was determined by the number of patients in the trial at the given week.

NA = not applicable; PR48= peginterferon-ribavirin regimen; BOC/RGT = Response Guided Therapy; BOC/PR48 peginterferon–ribavirin-boceprevir regimen